JP2021519580A5 - - Google Patents
Info
- Publication number
- JP2021519580A5 JP2021519580A5 JP2020552225A JP2020552225A JP2021519580A5 JP 2021519580 A5 JP2021519580 A5 JP 2021519580A5 JP 2020552225 A JP2020552225 A JP 2020552225A JP 2020552225 A JP2020552225 A JP 2020552225A JP 2021519580 A5 JP2021519580 A5 JP 2021519580A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- domain containing
- signaling domain
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649499P | 2018-03-28 | 2018-03-28 | |
| US62/649,499 | 2018-03-28 | ||
| PCT/US2019/024441 WO2019191339A1 (en) | 2018-03-28 | 2019-03-27 | Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021519580A JP2021519580A (ja) | 2021-08-12 |
| JP2021519580A5 true JP2021519580A5 (https=) | 2022-04-04 |
| JPWO2019191339A5 JPWO2019191339A5 (https=) | 2022-04-04 |
| JP7549533B2 JP7549533B2 (ja) | 2024-09-11 |
Family
ID=66626002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020552225A Active JP7549533B2 (ja) | 2018-03-28 | 2019-03-27 | キメラ貪食受容体のための発現ベクター、遺伝子改変宿主細胞およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210024607A1 (https=) |
| EP (1) | EP3774869A1 (https=) |
| JP (1) | JP7549533B2 (https=) |
| KR (1) | KR20210024441A (https=) |
| CN (1) | CN112218886B (https=) |
| AU (1) | AU2019243153A1 (https=) |
| CA (1) | CA3093969A1 (https=) |
| IL (1) | IL277587A (https=) |
| MX (1) | MX2020010235A (https=) |
| RU (1) | RU2020135106A (https=) |
| WO (1) | WO2019191339A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4089116A1 (en) | 2016-09-27 | 2022-11-16 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| EP3688032B1 (en) | 2017-09-26 | 2025-11-05 | Cero Therapeutics Holdings, Inc. | Chimeric engulfment receptor molecules and methods of use |
| WO2019191334A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| JP7444781B2 (ja) | 2018-03-28 | 2024-03-06 | セロ・セラピューティクス・インコーポレイテッド | 細胞免疫療法組成物およびその使用 |
| WO2021067875A1 (en) | 2019-10-03 | 2021-04-08 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| CN115943205A (zh) * | 2020-04-23 | 2023-04-07 | 加利福尼亚大学董事会 | 基因工程吞噬细胞以及相关组合物、载体、方法和系统 |
| WO2022036285A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase |
| CA3189328A1 (en) * | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
| WO2022036265A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
| WO2022036287A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
| CN112194726B (zh) * | 2020-09-02 | 2023-06-23 | 沣潮医药科技（上海）有限公司 | 用于病理性蛋白聚集物清除的嵌合抗原受体及其应用 |
| CA3197423A1 (en) * | 2020-11-04 | 2022-05-12 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| CN116916940A (zh) * | 2020-11-04 | 2023-10-20 | 美洛德生物医药公司 | 工程化嵌合融合蛋白组合物及其使用方法 |
| US20240033356A1 (en) * | 2020-11-18 | 2024-02-01 | Carina Biotech Pty Ltd | Chimeric antigen receptor t cell and method |
| US20240148868A1 (en) * | 2021-03-18 | 2024-05-09 | University Of Florida Research Foundation, Incorporated | Chimeric phagocytic receptors for treatment of neurodegenerative disorders |
| EP4330272A1 (en) * | 2021-04-28 | 2024-03-06 | Sanquin IP B.V. | Chimeric fc-alpha receptors and uses thereof |
| WO2022234976A1 (ko) * | 2021-05-04 | 2022-11-10 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| WO2023286088A1 (en) * | 2021-07-16 | 2023-01-19 | Indian Institute Of Science Education And Research Bhopal | Methods and compositions for viral vector transduction |
| JP2024529474A (ja) | 2021-07-28 | 2024-08-06 | セロ・セラピューティクス・インコーポレイテッド | キメラＴｉｍ４受容体およびその使用 |
| WO2023076993A1 (en) * | 2021-10-28 | 2023-05-04 | The Regents Of The University Of California | Methods of treating lymphoma with a phagocyte having a chimeric antigen receptor |
| KR20250029302A (ko) * | 2022-03-01 | 2025-03-04 | 헤모제닉스 파마슈티컬스 엘엘씨 | 키메라 미끼 수용체 및 이의 용도 |
| US20250195573A1 (en) * | 2022-03-18 | 2025-06-19 | The Regents Of The University Of Colorado, A Body Corporate | Genetically engineered t-cell co-receptors and methods of use thereof |
| CN114806912A (zh) * | 2022-04-06 | 2022-07-29 | 中国海洋大学 | 高效表达菌丝霉素的重组工程菌及其应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| TW225528B (https=) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| EP0907642B1 (en) | 1996-06-24 | 2005-11-02 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US8709412B2 (en) * | 2001-06-29 | 2014-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of TIM receptor activity in combination with cytoreductive therapy |
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| AU2008298948B2 (en) | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP2906684B8 (en) | 2012-10-10 | 2020-09-02 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| WO2015066262A1 (en) | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| IL290655B2 (en) | 2014-05-29 | 2024-05-01 | Us Health | Anti-human papillomavirus 16 E7 T-cell chelates |
| ES2781175T3 (es) * | 2014-07-31 | 2020-08-31 | Novartis Ag | Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico |
| CN107995913B (zh) | 2015-05-18 | 2022-02-11 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| RU2766690C2 (ru) * | 2015-07-28 | 2022-03-15 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения |
| WO2018031419A1 (en) * | 2016-08-12 | 2018-02-15 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens |
| EP4089116A1 (en) * | 2016-09-27 | 2022-11-16 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| EP3876977A1 (en) * | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
-
2019
- 2019-03-27 RU RU2020135106A patent/RU2020135106A/ru unknown
- 2019-03-27 CA CA3093969A patent/CA3093969A1/en active Pending
- 2019-03-27 CN CN201980035719.XA patent/CN112218886B/zh active Active
- 2019-03-27 JP JP2020552225A patent/JP7549533B2/ja active Active
- 2019-03-27 WO PCT/US2019/024441 patent/WO2019191339A1/en not_active Ceased
- 2019-03-27 MX MX2020010235A patent/MX2020010235A/es unknown
- 2019-03-27 US US17/040,464 patent/US20210024607A1/en not_active Abandoned
- 2019-03-27 EP EP19725783.5A patent/EP3774869A1/en active Pending
- 2019-03-27 AU AU2019243153A patent/AU2019243153A1/en not_active Abandoned
- 2019-03-27 KR KR1020207029512A patent/KR20210024441A/ko not_active Ceased
-
2020
- 2020-09-24 IL IL277587A patent/IL277587A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519580A5 (https=) | ||
| RU2020135106A (ru) | Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения | |
| JP2021519301A5 (https=) | ||
| RU2020135107A (ru) | Клеточные иммунотерапевтические композиции и их применения | |
| JPWO2019191339A5 (https=) | ||
| JPWO2019191340A5 (https=) | ||
| JP2022113880A5 (https=) | ||
| JP2021514631A5 (https=) | ||
| JP2018521628A5 (https=) | ||
| JP7725031B2 (ja) | Ｃｄ７を標的にするキメラ抗原受容体及びその使用 | |
| AU2016343809B2 (en) | Compositions and methods for treatment of cancer | |
| JP2020511136A5 (https=) | ||
| JP2025028239A5 (https=) | ||
| JP2020114264A5 (https=) | ||
| WO2017176525A1 (en) | Car having replicated binding motifs in a co-stimulatory domain | |
| JP2018508219A5 (https=) | ||
| JP2015527070A5 (https=) | ||
| JP2020517295A5 (https=) | ||
| Peipp et al. | Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer | |
| JP2023527530A (ja) | 同種異系移植のための操作された免疫細胞 | |
| CA3054304A1 (en) | Compositions and methods for treatment of cancer | |
| JP2021532742A5 (https=) | ||
| JP2017531687A5 (https=) | ||
| US12077598B2 (en) | Chimeric antigen receptors with mutated CD28 phosphorylation sites | |
| Liu et al. | Structures of immune checkpoints: an overview on the CD28-B7 family |